Default company panoramic image

PROMOT2E Therapeutics

We are developing novel targeted nano technologies for the treatment of cancer and other diseases of high unmet need

  • Stage Product In Development
  • Industry Biotechnology
  • Location Laval, QC, Canada
  • Currency CAD
  • Founded January 2012
  • Employees 7
  • Website

Company Summary

We are a startup R&D company spun out from Labopharm Inc. using novel PROMOT2E technology to enable tissue-specific gene silencing via the RNAi pathway. We intend to first validate our technology platform, comprising synergistic novelmicelle/ novel siRNA compositions in vivo and monetize it via technology outlicening. We will then develop our own product candidates for outlicensing after preclinical validation but prior to clinical testing


  • Default avatar
    Damon Charles Smith Ph.D

    Seasoned pharma R&D executive with 23 years of international experience in EU, Australia and N. America. Extensive discovery to approval expertise with protein, peptide, oligonucleotide and small molecule drugs. Devised & commissioned R&D/Quality operations for three high growth Co. Lead R&D programmes for multiple approved products and a key member of senior management for three successful IPO’s

  • Default avatar
    Sylvain Guenette CA

    Sylvain Guénetteis Chief Financial Officer of Labopharm Inc. Prior to joining Labopharm, Mr. Guénette was Corporate Controller at Les Systèmes Proxima Ltée from August 2001 to August 2002. From 1999 to 2001, he was Director of finance and operations of the Montreal Office of Nurun Inc. and held various positions within the Quebecor group from 1994 to 1999.

  • Default avatar
    Corinne Benquet Ph.D
    Director of Research

    Corinne Benquet PhD has over 14 years experience in the biotechnology/pharmaceutical industry, with extensive experience in early development projects. She has managed and implemented research and development programs for numerous molecules and therapeutic areas including oncology, endocrinology, analgesia and depression. Corinne held different progressive positions at Compatigène, Conjuchem Biotechnologies, Aurelium Biopharma and Labopharm


  • Default avatar
    Paladin Inc.
    Default avatar
    Sylvain Guenette

Previous Investors

  • Default avatar
    Paladin laboratories
    Default avatar
    Labopharm Inc.